AdoRx Therapeutics, a UK based drug discovery company, and Johnson & Johnson are teaming up to develop novel therapeutics for the treatment of lung cancer. As part of the strategic collaboration, AdoRx has granted an exclusive option to research, develop and commercialize novel antagonists within the AdoRx portfolio, and the groups will collaborate on drug discovery and preclinical development activities. AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer-based on
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
ICON Acquires Precision Medicine for Oncology Company MolecularMD
ICON, a global provider of drug development solutions and services has acquired MolecularMD, a molecular diagnostic specialty laboratory that enables the development and commercialization of precision medicines in oncology. The acquisition of MolecularMD’s extensive scientific and clinical biomarker experience expands the ICON’s capabilities in molecular diagnostic testing and also adds expanded testing platforms, including next-generation sequencing and immunohistochemistry, to ICON’s
Read More
Accenture Launches Life Science Open Partner Ecosystem to Advance Drug Discovery
Accenture, today announced it has created an open partner ecosystem developed in partnership with Merck and Amazon Web Services (AWS) designed to help independent software vendors (ISVs) and life sciences companies team more effectively to accelerate drug discovery efforts and, ultimately, improve patient outcomes.Life Sciences Partner Ecosystem Overview Built on Amazon Web Services and supported by ongoing work between Accenture and AWS through the Accenture AWS Business Group, the platform is
Read More
H1 Launches ‘Strategy as a Service’ Offering for Life Science Companies
H1, a company helping healthcare organizations with live data insights to help fight diseases, today launched a new Strategy as a Service offering designed to help clients accelerate the market research phase of drug development.The company’s new DaVinci service begins at $10,000, which can help clients cut time-to-market in half, spans:- Market Landscape: Validate your strategy against an up-to-date, comprehensive picture of products and patient needs in your market.- Competitive
Read More
Accenture, Merck, Amazon Team Up to Launch Cloud-based Informatics Platform for Life Sciences
In the Life Sciences research space, there has been a tendency to underinvest in technology. As a result, much of the current infrastructure is outdated, fragmented and unable to keep up with breakthroughs in modern science and technology.To help solve this technology challenge, Accenture, Merck and Amazon Web Services (AWS) are announcing a new, pre-competitive collaboration to launch a cloud-based informatics platform that will allow Life Sciences companies improve productivity, efficiency,
Read More
nference Raises $11M to Synthesize the World’s Biomedical Knowledge
nference, a Cambridge, MA-based company on a mission to synthesize the exponentially growing biomedical knowledge has raised $11 million in Series A funding led by Matrix Partners. The round also included participation from existing investor Matrix Capital Management. The company plans to utilize the funding to develop the company’s AI and R&D platforms, expand scientific operations in Cambridge MA and establish nference Labs in Bangalore, India.Founded by Murali Aravamudan and Venky
Read More
Vanderbilt University to Use $65M to Support Innovative Life Sciences Research
Deerfield Management and Vanderbilt University announced today the launch of Ancora Innovation, LLC ("Ancora"), a Deerfield company that will support Vanderbilt's innovative life science research and leverage Deerfield's expertise in accelerating state-of-the-art drug development. Ancora will fund projects with the aim of changing the current paradigm of drug development and establishing novel therapeutics to cure life-altering diseases.As part of Ancora, Deerfield will commit up to $65 million
Read More
AI-Driven Drug Discovery Startup twoXAR Lands $10M for Computational Platform
twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, announced today that it has raised $10 million in Series A financing led by SoftBank Ventures including follow-on participation from seed investor Andreessen Horowitz. The biotech startup plans to use the funding to build the company’s drug pipeline through partnerships and accelerate preclinical development of existing candidates. Traditional drug discovery and development is estimated to take 10-15 years and
Read More
Atomwise Raises $45M for Artificial Intelligence Platform for Drug Discovery
Atomwise, a San Francisco, CA-based company that develops artificial intelligence systems for drug discovery has raised $45 million in Series A funding led by Monsanto Growth Ventures, B Capital Group and Data Collective. Prior investors Y Combinator, Khosla Ventures, and DFJ also participated in this Series A financing, along with new investors Baidu Ventures, Tencent, and Dolby Family Ventures. The oversubscribed round brings Atomwise’s total capital raised to more than $51 million.Founded in
Read More
Engine Biosciences Lands $10M for AI-Driven Drug Discovery Platform
Engine Biosciences("Engine"), a San Francisco, CA-based biotech company pioneering its artificial intelligence and genomics network biomedicine platform for drug discovery has raised $10 million. The seed round was co-led by by DHVC (Danhua Capital) and 6 Dimensions Capital, with participation from global biopharmaceutical leader WuXi AppTec, EDBI, Pavilion Capital, Baidu Ventures, WI Harper, and Nest.Bio Ventures.The company plans to utilize the funding to support its proprietary platform,
Read More
